Keywords
Treatments
Nanoformulations
Efficiency
Dermatology
How to Cite
Abstract
The aim was to discuss the exploration of pathophysiology, current solutions, safety aspects and futuristic views of nanoformulations for atopic dermatitis. An integrative review of the literature indexed in the journal portal Scientific Electronic Library Online, Medical Literature Analyzes and Retrieval System Online and Latin American and Caribbean Literature in Health Sciences was carried out. 11 studies were selected. It was found that approaches have been employed to repair skin barrier function and control skin inflammation in patients with atopic dermatitis. With the help of ingenious nanocarriers, new approaches can be demonstrated by combining with novel administration routes for the successful optimization potential of skin-targeted nanoparticulate systems for the management of atopic dermatitis. It is concluded that nanomedicines, as drug carriers, appear to offer superior activity, including increased therapeutic efficacy with lower toxicity from small doses, drug localization, and specific drug targeting.
References
Kulig K, Rogóż W, Owczarzy A, Szkudlarek A, Maciążek-Jurczyk M. Material engineering for atopic dermatitis treatment. Med Res J. 2020;5(2):110-5. doi: 10.5603/MRJ.a2020.0012
Rajagopalan M, De A, Godse K, Krupa Shankar DS, Zawar V, Sharma N, et al. Guidelines on management of atopic dermatitis in India: an evidence-based review and an expert consensus. Indian J Dermatol. 2019;64(3):166-81. doi: 10.4103/ijd.IJD_683_18
Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181-92. doi: 10.2147/CCID.S163814
Oliveira JAM. Dermatite atópica: dos tratamentos farmacológicos clássicos aos novos sistemas de libertação de fármacos [Dissertação]. Faculdade de Farmácia da Universidade de Coimbra; Farmácia de Celas e Infarmed; 2019.
Neves KC, Araújo STC, Ribeiro WA, Silva JG, Azevedo AL, Paula E, Cirino HP, Amaral FS, Santana PPC, Correa FCC. A pele como território mínimo corporal e os cuidados de enfermagem às manifestações cutâneas na nefroclínica. Glob Clin Res. 2022;2(2):e28. doi: 10.5935/2763-8847.20220028.
Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for drug delivery and cosmetic moisturizers: review and comparison. Pharmaceutics. 2021;13(12):2012. doi: 10.3390/pharmaceutics13122012
Bardin L. Análise temática de conteúdo. Lisboa: Edições 70; 2021.
Damiani G, Eggenhöffner R, Pigatto PDM, Bragazzi NL. Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature. Bioact Mater. 2019;4:380-6. doi: 10.1016/j.bioactmat.2019.11.003
Burster T, Mustafa Z, Myrzakhmetova D, Zhanapiya A, Zimecki M. Hindrance of the proteolytic activity of neutrophil-derived serine proteases by serine protease inhibitors as a management of cardiovascular diseases and chronic inflammation. Front Chem. 2021;9:784003. doi: 10.3389/fchem.2021.784003
Ghosh N, Mitra S, Banerjee ER. Therapeutic effects of topically administered guar gum nanoparticles in oxazolone-induced atopic dermatitis in mice. Biomed Res Ther. 2019;5:2305-25.
Chu CY, Yao TC, Shih IH, Yang CY, Chin CL, Ibrahim SBBK, et al. Pimecrolimus for the treatment of atopic dermatitis in infants: an Asian perspective. Dermatol Ther (Heidelb). 2023;13(3):717-27. doi: 10.1007/s13555-022-00886-9
Gehrcke M, [additional authors if known]. Filmes de polissacarídeos naturais para a veiculação cutânea de nanocápsulas de silibinina no tratamento da dermatite atópica [Tese]. Santa Maria: Universidade Federal de Santa Maria; 2022.
Almeida MC. Relatório de Estágio e Monografia intitulada "Transporte de Fármacos no Tratamento da Dermatite Atópica" [Dissertação]. Faculdade de Farmácia da Universidade de Coimbra, Farmácia Machado-Coimbra; 2020.
Oliveira LF, Gazzi R, Paese K. Nanotecnologia aplicada no desenvolvimento de formulações despigmentantes [Trabalho de Conclusão de Curso]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2021.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Global Clinical Research Journal